Lanadelumab
- Generic Name
- Lanadelumab
- Brand Names
- Takhzyro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1426055-14-2
- Unique Ingredient Identifier
- 2372V1TKXK
- Background
Lanadelumab, also known as DX-2930, is a human IgG1 monoclonal antibody designed for subcutaneous self-injection. It is a fully human immunoglobulin, k-light-chain made in recombinant Chinese Hamster Ovary cells. The FDA and EU granted the designation of priority review, breakthrough therapy and orphan drug for rare diseases based on the results of the repor...
- Indication
Lanadelumab is indicated for the prophylaxis treatment to prevent attacks in adult and pediatric patients aged 2 years and older with hereditary angioedema.
...
- Associated Conditions
- Acute attacks of hereditary angioedema, Recurrent Angioedema
- Associated Therapies
- -
A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)
- First Posted Date
- 2022-07-15
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Takeda
- Target Recruit Count
- 20
- Registration Number
- NCT05460325
- Locations
- π¨π³
Yantai Yuhuangding Hospital, Yantai, Shandong, China
π¨π³Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, China
π¨π³The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
A Survey of Lanadelumab in Participants With Hereditary Angioedema
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Takeda
- Target Recruit Count
- 100
- Registration Number
- NCT05397431
- Locations
- π―π΅
Takeda selected site, Tokyo, T, Japan
Inhibition of Plasma Kallikrein as a New Therapy for Lung Injury
- Conditions
- Interventions
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- St Vincent's Institute of Medical Research
- Target Recruit Count
- 48
- Registration Number
- NCT04848272
- Locations
- π¦πΊ
St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia
Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients
- Conditions
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 515
- Registration Number
- NCT04590586
- Locations
- πΊπΈ
The University of Iowa, Iowa City, Iowa, United States
πΊπΈSharp Chula Vista Medical Center, Chula Vista, California, United States
π·πΊSPb SBIH "Alexandrovskaya City Hospital", Saint Petersburg, Russian Federation
A Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lanadelumab Administered Intravenously in Healthy Adult Volunteer Participants
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2022-03-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 12
- Registration Number
- NCT04503603
- Locations
- πΊπΈ
Celerion, Lincoln, Nebraska, United States
Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2020-10-12
- Lead Sponsor
- Shire
- Registration Number
- NCT04460105
A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Shire
- Target Recruit Count
- 73
- Registration Number
- NCT04444895
- Locations
- πΊπΈ
Optimed Research, LTD, Columbus, Ohio, United States
ππΊSemmelweis Egyetem, Budapest, Hungary
π³π±Universitair Medisch Centrum Groningen, Groningen, Netherlands
Lanadelumab in FXII-associated Cold Autoinflammatory Syndrome (FACAS)
- Conditions
- Interventions
- First Posted Date
- 2020-02-20
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 4
- Registration Number
- NCT04278885
- Locations
- π©πͺ
Charite University, Berlin, Germany, Berlin, Germany
A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
- First Posted Date
- 2019-12-20
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 77
- Registration Number
- NCT04206605
- Locations
- πΊπΈ
University of South Florida Asthma, Allergy & Immunology, Tampa, Florida, United States
π©πͺUniversitaetsklinikum Leipzig AoeR, Leipzig, Sachsen, Germany
πΊπΈMedical Research of Arizona, Scottsdale, Arizona, United States
Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE)
- First Posted Date
- 2019-11-27
- Last Posted Date
- 2022-09-30
- Lead Sponsor
- Shire
- Target Recruit Count
- 12
- Registration Number
- NCT04180163
- Locations
- π―π΅
Kobe University Hospital, Kobe-shi, Hyogo-Ken, Japan
π―π΅Asahi General Hospital, Asahi-shi, Chiba-Ken, Japan
π―π΅Ogaki Municipal Hospital, Ogaki-shi, Gifu-Ken, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.